MedWatch

Analyst predicts that covid-19 will still affect Demant

On Tuesday morning, Demant will present its interim management statement for Q1, in which it is expected that corona will play a significant role. The firm will also report on the reception of Oticon More.

Demant CEO Søren Nielsen | Photo: Kenneth Lysbjerg Koustrup/ERH

Covid-19, increasing infection rates and restrictions in many markets will keep being significant in Danish hearing aid firm Demant's communication when the firm presents its interim management statement for Q1 early on Tuesday.

The statement will not contain any actual figures, and since it encompasses the month of April, Demant will probably announce that in spite of the coronavirus, growth has got back into the positive figures for the last part of this time period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs